KENNETH R HESS to Predictive Value of Tests
This is a "connection" page, showing publications KENNETH R HESS has written about Predictive Value of Tests.
Connection Strength
0.238
-
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol. 2006 Sep 10; 24(26):4236-44.
Score: 0.038
-
Clinical trial design for microarray predictive marker discovery and assessment. Ann Oncol. 2004 Dec; 15(12):1731-7.
Score: 0.034
-
Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget. 2016 Sep 27; 7(39):64421-64430.
Score: 0.019
-
Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. Cancer. 2014 Jul 01; 120(13):1932-8.
Score: 0.016
-
Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Res Treat. 2013 Jan; 137(2):631-6.
Score: 0.015
-
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res. 2011 Jun 15; 13(3):R67.
Score: 0.013
-
Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold? Ann Oncol. 2011 Nov; 22(11):2387-2393.
Score: 0.013
-
Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res. 2010 Nov 01; 16(21):5351-61.
Score: 0.013
-
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol. 2010 Aug; 28(8):827-38.
Score: 0.013
-
Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol. 2008 Sep 20; 26(27):4442-8.
Score: 0.011
-
Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol. 2005 Nov 20; 23(33):8331-9.
Score: 0.009
-
Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005 Aug 15; 11(16):5678-85.
Score: 0.009
-
Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival, and reveals clinically-relevant novel glioma subsets. Brain Pathol. 2002 Jan; 12(1):108-16.
Score: 0.007
-
A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001 Aug; 95(2):190-8.
Score: 0.007
-
Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol. 2000 Feb; 18(3):646-50.
Score: 0.006
-
p53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer. Clin Cancer Res. 1997 Oct; 3(10):1685-90.
Score: 0.005
-
Screening for colorectal cancer. A comparison of 3 fecal occult blood tests. Arch Intern Med. 1997 May 12; 157(9):970-6.
Score: 0.005
-
Pelvic exenteration for locally advanced rectal carcinoma: factors predicting improved survival. Surgery. 1997 May; 121(5):479-87.
Score: 0.005